Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Simpson, D. J.
Right arrow Articles by Farrell, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpson, D. J.
Right arrow Articles by Farrell, W. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 8, 1149-1154, August 2001
© 2001 Oxford University Press

CANCER BIOLOGY

Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas

David J. Simpson, Simon J. Frost, John E. Bicknell, John C. Broome1,, Anne Marie McNicol2,, Richard N. Clayton and William E. Farrell3,

Centre for Cell and Molecular Medicine, School of Postgraduate Medicine, Keele University, North Staffordshire Hospital, Stoke on Trent ST4 7QB,
1 Department of Neuropathology, Walton Centre for Neurology and Neurosurgery, NHS Trust, Lower Lane, Fazakerley, Liverpool L9 7LJ and
2 University Department of Pathology, Glasgow Royal Infirmary, Glasgow G4 0SF, UK

Components of the pRb/p16/cyclin D1/CDK4 pathway are frequent targets in numerous tumour types, including those of pituitary origin. However, previous studies of pituitary tumours have examined individual components of this pathway. Therefore, to determine their overall contribution we have simultaneously examined the immunohistochemical status of pRb, p16 and cyclin D1 and analysed the CDK4 gene for a characterized activating mutation. Of the total pituitary tumour cohort (29 clinically non-functioning adenomas and 16 somatotrophinomas) abnormal expression of either pRb, p16 or cyclin D1 was observed in 36 of 45 (80%) tumours and was significantly (P = 0.005) associated with non-functioning tumours (27/29; 93%) compared with somatotrophinomas (9/16, 56%). Loss of either pRb or p16 expression was mutually exclusive in 23 of 45 (51%) tumours, whilst concomitant loss of pRb and p16 expression was observed in five tumours. Cyclin D1 overexpression was observed in 22 of 45 (49%) tumours, however, there was no significant association between overexpression of cyclin D1 and the expression status of either pRb or p16. In addition, no activating mutations within codon 24 of the CDK4 gene were detected. This study provides evidence for the first time that components of the pRb/p16/cyclin D1/CDK4 pathway, either alone or in combination, are frequently deregulated in human pituitary tumours, suggesting that this pathway may be a useful target in drug or gene therapeutic approaches.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
V. Quereda and M. Malumbres
Cell cycle control of pituitary development and disease
J. Mol. Endocrinol., February 1, 2009; 42(2): 75 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M Musat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S Jordan, D G Morris, M Gueorguiev, et al.
Enhanced protein kinase B/Akt signalling in pituitary tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 423 - 433.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Simpson, A. M. McNicol, D. C. Murray, A. Bahar, H. E. Turner, J. A. H. Wass, M. M. Esiri, R. N. Clayton, and W. E. Farrell
Molecular Pathology Shows p16 Methylation in Nonadenomatous Pituitaries from Patients with Cushing's Disease
Clin. Cancer Res., March 1, 2004; 10(5): 1780 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Lu, A. B. Gladden, and J. A. Diehl
An Alternatively Spliced Cyclin D1 Isoform, Cyclin D1b, Is a Nuclear Oncogene
Cancer Res., November 1, 2003; 63(21): 7056 - 7061.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.